The Cancer Advisor

Exciting results for a new first line option in PD-L1+ mTNBC (pretreated metastatic TNBC). Background: Although PD-1/PD-L1* inhibitors plus chemo have expanded treatment options for previously untreated PD-L1–positive advanced TNBC, there still remains a critical unmet need to improve outcomes. SG previously demonstrated significant clinical benefit in pretreated metastatic TNBC (mTNBC). We report results from the ASCENT-04/KEYNOTE-D19 study   in patients with previously untreated, PD-L1–positive (CPS ≥ 10; 22C3 assay) locally advanced unresectable or mTNBC. Note: PD-L1 stands for programmed death ligand 1. It's a protein found on some normal cells and can be expressed on cancer cells. It acts as a brake on the immune system, preventing T cells from attacking other cells, including cancer cells. When PD-L1 binds to another protein called PD-1, it inhibits T cell activity. ( National Cancer Institute ) Methods: Patients were randomized 1:1 to SG (10 mg/kg IV, day 1 & 8) + pembro...

Many of us have been personally affected by cancer — including me. I’m an oncologist, and my own family history is one of the reasons I decided to specialize in caring for people with cancer and in conducting cancer research. My mom has lung cancer, and several relatives from both my mom and my dad’s side were also diagnosed with cancers. It’s no wonder I worry about cancer affecting me one day. Credit: Cancer Care (2nd Edition) About 1 in 5 people around the world will  develop cancer  throughout the course of their lives. In 2021, almost 1.8 million  new cancer cases  were reported in the United States, according to the Centers for Disease Control and Prevention. The following year, about 600,000 people died of cancer in the country. But there are steps you can take to reduce your risk. About 40 percent of new cancer diagnoses in U.S. adults age 30 and older are considered preventable, according to a  study  from the American Cancer Society. Here are 11...

Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...